Poster Session B  
Friday, November 16, 2018  
17:15–19:30

B001 A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with glioblastoma multiforme in The Cancer Genome Atlas Dataset. Bum-Sup Jang, Seoul National University Hospital, Seoul, Republic of Korea.

B002 A negative prognostic impact of radiotherapy-induced lymphopenia in patients with breast cancer. Chang Ik Yoon, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

B003 The effects of high-intensity focused ultrasound (histotripsy) on tumor immune microenvironment. Cheol-Hee Shin, Center for Biomaterials, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.

B004 Clinicopathologic significance of CD57-positive immune cells and NK cell activity modulators in microsatellite unstable and stable colorectal cancer. Hee Youn Na, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-Do, Republic of Korea.

B005 Optimization of human monoclonal antibody Ab417 for the treatment of malignant cancers. HEESU CHAE, Kangwon National University, Chuncheon, Republic of Korea.

B006 Differential impact of chemotherapy on a cancer vaccine based immunotherapy regimen (VBIR) induced immunogenicity in cynomolgus macaques. Helen Cho, Pfizer, La Jolla, CA, USA.

B007 Optimal combination of intratumoral oncolytic virus and immune checkpoint blockade enhances anticancer immune response. Hong Jae Chon, Medical Oncology, CHA Bundang Medical Center, Gyeonggi-do, Republic of Korea.

B008 Heterogeneous exhaustion status of tumor-infiltrating CD8+ T cells determines distinct subgroups of hepatocellular carcinoma patients. Hyung-Don Kim, KAIST, Daejoen, Republic of Korea.

B009 Assay comparability of 22C3 and SP263 immunohistochemistry staining in lung cancer: 1254 paired cases in real clinical practice in a single institution. Hyunjin Kim, Samsung Medical Center, Seoul, Republic of Korea.

B010 Anti-tumor immune responses by dendritic cells pulsed with cancer stem cell antigen. Hyunmi Park, Wide River Institute of Immunology, Hongcheon, Republic of Korea.
Poster Session B
Friday, November 16, 2018
17:15–19:30

B011 Curcumin and EGCG repress multiple immune check-point ligands regardless of tumor microenvironment in HNSCC. Jaewon Chang, Research Institute for Medical Science, Chungnam National University, College of Medicine, Daejeon, Chungchungnam-Do, Republic of Korea.

B012 Discovery of tumor-specific regulatory T cell activation marker (RTA). Jae-Won Cho, Yonsei University, Seoul, Republic of Korea.


B014 Type I interferon signaling sustained during chronic viral infection directly augment NK cell-mediated immunosurveillance for cancer. Ji Hoon Oh, Yonsei University, Seoul, Republic of Korea.

B015 Anti-PD-1-induced reinvigoration of tumor-infiltrating CD8+ T cells is determined by their differentiation status in glioblastoma. Junsik Park, Korea Advanced Institute Science and Technology, Daejeon, Republic of Korea.


B017 Comprehensive molecular profiling reveals distinct immune microenvironment subtypes of oropharyngeal cancers. Min Hwan Kim, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

B018 PD-1 blockade reinvigorates bone marrow CD8+ T cells from patients with multiple myeloma in the presence of TGF-β inhibition. Minsuk Kwon, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.

B019 Abundance of Treg cells in oral cancer patients and effects of their inhibition on growth of cancer cells. Sadhna Aggarwal, AIIMS, New Delhi, Delhi, India.


B021 The synergistic effect of CKD-516 combined with immune checkpoint inhibitors. Soo Jin Kim, CKD Research Institute, Yongin, Gyeonggi-go, Republic of Korea.
Poster Session B
Friday, November 16, 2018
17:15–19:30

B022 Differences in immune microenvironment between EGFR mutant and EGFR wild type NSCLC. Sook-hee Hong, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

B023, PP7 Multiplex three-dimensional imaging cytometry for mapping tumor immune microenvironment. Steve Seung-Young Lee, University of Illinois at Chicago, Chicago, IL, USA.

B024 Synergic effect by the combination treatment of immune checkpoint inhibitor and radiotherapy in mouse fibrosarcoma model. Sun Hyun Bae, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.


B026, PP5 Myeloid-derived suppressor cells impair the anti-tumor activity of PD-1 blockade in gastric cancer. Woosook Kim, Columbia University, New York, NY, USA.

B027 Expression of immune checkpoint molecule on tumor-infiltrating lymphocytes in advanced colorectal cancer: The immune landscape analyzed by multiplex immunohistochemistry technique using computerized digital image. Yoonjin Kwak, Seoul National University Hospital, Seoul, Republic of Korea.


B029 The levels of CTC were significantly associated with the BDNF and VEGF-D in plasma and their factors mediated somatic mutation was detected in CTC enumerated by PCASI. Bong-Seog Kim, VHS Medical Center, Seoul, Republic of Korea.

B030 Simple and low-cost cell-free nucleic acids isolation microfluidic platform from liquid biopsies of cancer patients. Choong Eun Jin, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.


**Poster Session B**

**Friday, November 16, 2018**  
17:15–19:30

**B033** The potential of KRAS mutation in circulating-tumor DNA as a marker for prognosis in patients with pancreatic cancer. Min Kyeong Kim, National Cancer Center, Goyang, Gyeonggi, Republic of Korea.

**B034** Feasibility of target-specific liquid biopsy using irradiation on two-tumor mouse model. Won-Gyun Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

**B035** Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53. Hyeon Ju Lee, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.

**B036** Nanocarrier composed of magnetite core coated with three polymeric shells mediates LCS-1 delivery for synthetic lethal therapy of BLM-defective colorectal cancer cells. Anas Ahmad, Institute of Nano Science and Technology (INST), Mohali, Punjab, India.

**B037** PI3K signalling in primary prostate cancer: A promising target for prostate cancer precision medicine. Andrew Erickson, Institute for Molecular Medicine Finland (FIMM), Helsinki Institute for Life Sciences (Hi-Life), University of Helsinki, Helsinki, Uusimaa, Finland.

**B038** Fibroblast growth factor 21 promotes tumor progression in differentiated thyroid cancer. Bon Seok Koo, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.

**B039** Targeting USP13-amplified ovarian cancer. Cecil Han, Georgetown University School of Medicine, Washington, D.C., USA.

**B040** PTBP1-mediated regulation of AXL mRNA stability plays a role in lung tumorigenesis. Chun-Yu Cho, National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.

**B041** The histone deacetylase inhibitor panobinostat is a potent antitumor agent in gastric cancer. Dayeah Kim, Chonbuk National University Medical School, Jeonju, Republic of Korea.

**B042** Targeting tyrosine kinase inhibitor-resistant non-small cell lung cancer by inducing epidermal growth factor receptor degradation via methionine 790 oxidation. Elaine Leung, Macau University of Science and Technology, Taip, Macau.
Poster Session B
Friday, November 16, 2018
17:15–19:30

B043 Targeting the mechanism leading to radiation-resistant renal cell carcinoma. Eun-Jin Yun, POSTECH, Pohang, Republic of Korea.

B044, PP6 Humanized N-cadherin monoclonal antibodies demonstrate efficacy in treatment of castration resistant prostate cancer. Evelyn Kono, David Geffen School of Medicine at UCLA, Department of Urology, Los Angeles, CA, USA.

B045 PARP1 expression in the high-grade neuroendocrine carcinoma of the lung. Hye Sook Kim, Myongji Hospital, Goyang, Republic of Korea.

B046 Identifying a molecular pathway that controls metastasis in uveal melanoma. Jae Hyuk Yoo, University of Utah, Salt Lake City, UT, USA.

B047 Interleukin-7 contributes the invasiveness of the prostate cancer cells PC-3 via promoting the epithelial-mesenchymal transition. Jin-Hee Kim, Cheongju University, Cheongju, Chungbuk, Republic of Korea.

B048 VEGF is the potential therapeutic target against triple-negative breast cancer patient-derived xenograft model. Jin-Sun Ryu, National Cancer Center, Goyang, Republic of Korea.

B049 Personal therapeutic approaches for small cell lung cancer with IRS2 amplification. Mi-Sook Lee, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

B050 Extracellular vesicle-derived circular RNAs as therapeutic targets for chemoresistant colorectal cancer. Nadiah Abu, UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.

B051 Urothelial carcinoma with trophoblastic differentiation. An under-recognized clinical entity. Nan-Haw Chow, National Cheng Kung University, Tainan, Taiwan.

B052 The crucial role of POU3F2 transcription factor in neuroendocrine prostate cancer. Naoko Kobayashi, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

B053 miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Peter Yu, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.

B054 Stromal estrogen receptor alpha and epithelial progesterone receptor are potential targets for cervical cancer. Sanghyuk Chung, University of Houston, Houston, TX, USA.
B055 Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer. Se Lim Kim, Chonbuk National University, Jeon-Ju, Chonbuk, Republic of Korea.

B056 BAP1 plays an essential role in colon cancer cell survival through INO80 stabilization. Seul-Gi Park, Ewha Womans University, Seoul, Republic of Korea.

B057 Inhibitory effect of Wnt/β-catenin inhibitor CWP232228 on the growth of ovarian cancer cells. Seungmee Lee, School of Medicine, Keimyung University, Daegu, Republic of Korea.

B058 Oncogenic miRNAs Expressions with breast cancer stem cells in breast carcinoma: A step towards precision medicine. Shailendra Dwivedi, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

B059 Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer. Sujin Lee, Seoul National University, Seoul, Republic of Korea.

B060 PRDX4 overexpression is associated poor prognosis in gastric cancer. Sun-Yi Park, Gyeongsang National University School of Medicine, Changwon / Jinju, Republic of Korea.

B061 CRISPR-Cas9 mediated-CD133 knockout effectively reduced cell proliferation, migration and invasion in CD133+ colon cancer cells. Wanlu Li, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.

B062 Salmonella inhibits tumor metastasis by down-regulation heparanase. Wen-Yi Chiou, National Sun Yat-sen University, Kaohsiung, Taiwan.

B063 Loss of LLGL1 promotes gemcitabine resistance by repressing OSMR in pancreatic ductal adenocarcinoma. Yangchao Chen, The Chinese University of Hong Kong, Hong Kong, China.

B064 Androgen deprivation–induced ZBTB46 signaling as a mechanism of castration-resistant prostate cancer. Yen-Nien Liu, Taipei Medical University, Taipei, Taiwan.

B065 Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells increases the potency of dedifferentiated liposarcoma. Yu Jin Kim, SKKU, Seoul, Seoul, Republic of Korea.
Poster Session B
Friday, November 16, 2018
17:15–19:30

B066 Salmonella-mediated cytolethal distending toxin transfer inhibits tumor growth. Che-Hsin Lee, National Sun Yat-sen University, Kaohsiung, Taiwan.


B068 Concordance between artificial intelligence and multidisciplinary tumor board for lung cancer. In-Jae Oh, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea.


B070 Non-thermal irreversible electroporation modulates the tumor microenvironment and metastatic potential of pancreatic cancer. Rebecca Brock, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.

B071 Advantages and molecular mechanisms of heavy-ion radiotherapy for refractory pancreatic cancer. Sei Sai, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.

B072 Therapeutic applications of next-generation antisense oligonucleotides (ASOs) to intervene hard-to-inhibit drug targets in oncology. Youngsoo Kim, Ionis Pharmaceuticals Inc., Carlsbad, CA, USA.


B074 Elucidation of dasatinib action in gastric cancer cells harnessing MS-based activity-based protein profiling. Eun Ji Jo, Graduate School of Analytical Science and Technology (GRAST), Chungnam National University, Daejeon, Republic of Korea.

B075 Personalized adaptive therapies for metastatic solid tumors: Phase i (imaginary) approach. Eunjung Kim, Moffitt Cancer Center, Tampa, FL, USA.

B076 Identification of MYBL2 and FOXM1 as key TFs in tumor progression using transcriptional regulatory networks. Heonjong Han, Yonsei University, Seoul, Seodaemun-gu, Republic of Korea.
**Poster Session B**

**Friday, November 16, 2018**

17:15–19:30

**B077 Computational oncology prediction model algorithm.** Hyunjo Kim, AUMC, Suwon, Kyeunggido, Republic of Korea.

**B078 Identification of novel prognostic markers using a neural network-based algorithm in lung adenocarcinomas and head and neck squamous cell carcinomas.** Jeong Seon Kim, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.

**B079 In silico drug repositioning of bortezomib to reverse metastatic effect of GALNT14 in lung cancer.** Ok-Seon Kwon, Seoul National University, Seoul, Republic of Korea.

**B080 Beta-catenin/TCF activity is a bio-marker for IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer.** Hani Lee, Sookmyung Women's University, Seoul, Republic of Korea.

**B081 Pectoralis major myocutaneous flap for reconstruction after oral cancer surgery in Indian scenario: Our experience in 200 patients.** Nikhil Garg, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.

**B082 Role of post-mastectomy radiotherapy in T1, T2 lesions with 1-3 positive axillary lymph nodes: Study of 101 cases.** Nikhil Garg, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.

**B083 Pediatric nasopharyngeal carcinoma: An analysis from developing country.** Pooja Gogia, Batra Hospital and Medical Research Center, New Delhi, Delhi, India.

**B084 Functional characterization of CREBBP and EP300 mutations as a key driver of small cell lung cancer.** Kwon-Sik Park, University of Virginia, Charlottesville, VA, USA.

**B085 The effect of multileaf collimator leaf width on the radiosurgery planning for spine lesion treatment in terms of the modulated techniques and target complexity.** Soo-Min Chae, Cheju Halla Hospital, Jeju, Republic of Korea.

**B086 The chronic intermittent hypoxia enhances cancer progression in lung cancer.** Sung Bae Cho, St. Paul's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

**B087 Comparison of the antioxidant activity of genistein and quercetin on ROS generation in different cell lines.** Veronika Lachová, Comenius University in Bratislava, Bratislava, Slovakia.
Poster Session B
Friday, November 16, 2018
17:15–19:30

B088, PP4 Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Joo Sang Lee, University of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA.

B089 Early prediction of chemotherapy response using $^{18}$F-FDG PET radiomics and deep learning approach in osteosarcoma patients. Wook Kim, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.

B090 Association of preoperative anemia and perioperative allogenic red blood cell transfusion with oncologic outcomes in patients with non-metastatic colorectal cancer. Young-Wan Kim, Yonsei University Wonju College of Medicine, Wonju-si, Republic of Korea.

B091 HN1 suppresses the growth of colorectal cancer cells by induction of Autophagy. Yu Chuan Liu, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Jeonlabuk-do, Republic of Korea.

B092 Identification of RhBMP-2 as a cell growth inhibitor in human pancreatic cancer cells via Suppression of YAP. Yu Chuan Liu, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Jeonlabuk-do, Republic of Korea.